Tuesday 20 August 2019

Reuters Health Report: AstraZeneca diabetes drug shows promise in heart failure

Reuters.com Newsletter

AstraZeneca diabetes drug shows promise in heart failure

AstraZeneca made strides on Tuesday toward its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly.

Elderly in Hong Kong looking to China for affordable care in retirement

After spending time with his 84-year-old mother in a senior care home in the southern Chinese city of Shenzhen, David Lee walked up to the supervisor and asked to reserve a place there for his own retirement.

Planned Parenthood opts out of U.S. subsidies in fight over abortion referrals

Planned Parenthood said on Monday it was withdrawing from a federal program subsidizing reproductive healthcare for low-income women after the Trump administration banned participants in the program from referring women to abortion providers.

FDA declines to approve Sarepta's second Duchenne treatment

Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the risk of infection and kidney toxicity.

African Americans need 24-hour blood pressure checks

NEW YORK (Reuters Health) - Measuring blood pressure outside the clinic using 24-hour monitoring equipment is important for identifying and managing hypertension in African-Americans, a new study shows.

Seniors at greater risk of choking on dietary supplements

(Reuters Health) - Seniors may be more likely than younger adults to choke on vitamins and dietary supplements, or to have other problems swallowing them, especially when the pills are on the larger side, a new study suggests.

Tobacco industry anti-smoking ads reached less than half of U.S. adults

(Reuters Health) - Court-ordered anti-smoking ads sponsored by the tobacco industry reached only around 40% of adults and about half of all smokers in the U.S., a recent study suggests.

Nabriva prices two pneumonia antibiotic versions at over $200 per day

Nabriva Therapeutics Plc on Monday priced an oral and injectable version of its antibiotic Xenleta, which treats community-acquired pneumonia, at more than $200 per day after it received approval from the U.S. Food and Drug Administration.

Who is next in big pharma's merger spree?

Consolidation in the U.S. healthcare industry, which has already witnessed a string of multi-billion dollar deals, is expected to remain a major theme for the rest of 2019.

Sleep quality may be linked with success during military basic training

(Reuters Health) - Soldiers who experience sleep problems during basic combat training may be more likely to struggle with psychological distress, attention difficulties, and anger issues during their entry into the military, a recent study suggests.

Study prompts call for lower fluoride consumption by pregnant women

(Reuters Health) - Adding fluoride to the water supply prevents tooth decay, but women who drink fluoridated water during pregnancy may also trim the IQs of their male children by a few points, according to a Canadian study that suggests a serious drawback to a long-established public health intervention.

Related Videos

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS